Miransertib is an allosteric, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively). It is selective for Akt isoforms over a panel of 303 other kinases. It binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. MW: 432.53. Purity ≥98% by HPLC